Your Front Row Seat to the Future of Cancer Care | Oncology News | Meeting Coverage | Clinical Trials | oncweekly.com
Joined November 2023
- Tweets 468
- Following 269
- Followers 67
- Likes 735
349 Photos and videos
22 Aug 2024
G6PD inhibition leads to oxidative stress and cell death in tumors, boosting the efficacy of immunotherapies. #Oncology #CancerTreatment #G6PD - buff.ly/3yA5eN8
23
19 Aug 2024
Patients with low G6PD expression have better outcomes with ICIs, suggesting a new therapeutic strategy. #CancerResearch #Immunotherapy #Oncology #LungCancer - buff.ly/3yA5eN8
28
16 Aug 2024
SRS/FSR for CSM yields high CNN recovery rates and long-term tumor control, with SRS showing quicker improvements. #Oncology #CancerCare #RadiationOncology #OncWeekly - buff.ly/3WMsbWG
39
14 Aug 2024
ML classifiers' accuracy in predicting PCR in breast cancer evaluated. #Oncology #CancerResearch #BreastCancer #MachineLearning #PrecisionOncology #OncWeekly - buff.ly/4bWDWhL
30
13 Aug 2024
Study shows low G6PD expression in tumors improves immune response and outcomes of immune checkpoint inhibitors. #CancerTreatment #Oncology #Immunotherapy #LungCancer #Melanoma - buff.ly/3yA5eN8
25
12 Aug 2024
Upfront resection in elderly glioblastoma patients significantly improves survival rates. Key finding for treatment approaches. #CancerResearch #Glioblastoma #Oncology - buff.ly/3WywBAH
22
12 Aug 2024
Study: SRS/FSR for CSM shows significant CNNs recovery and excellent long-term radiological control. #Oncology #CancerResearch #Radiology #OncWeekly - buff.ly/3WMsbWG
11
8 Aug 2024
Upfront resection improves survival in elderly glioblastoma patients, study reveals. buff.ly/3WywBAH
22
7 Aug 2024
Study shows COX-2 overexpression is linked to worse prognosis in breast cancer, correlated with TNM staging and histological grading. #BreastCancer #Oncology #COX2 - buff.ly/4d8ApOG
23
6 Aug 2024
G6PD inhibition triggers immunogenic cell death, enhancing immunotherapy effectiveness against tumors. #CancerResearch #Immunotherapy #G6PD #Oncology #LungCancer #Melanoma - buff.ly/3yA5eN8
43
6 Aug 2024
FDA reviews Immorta Bio's Senovax IND application for NSCLC. Potential breakthrough in lung cancer treatment on the horizon. #NSCLC #LungCancer #OncologyNews - buff.ly/4cglDUS
27
5 Aug 2024
Study compares ML classifiers for predicting PCR in breast cancer. #Oncology #CancerResearch #BreastCancer #MachineLearning #ClinicalTrials #OncWeekly - buff.ly/4bWDWhL
27
5 Aug 2024
SRS/FSR treatments for CSM lead to effective cranial nerve recovery and sustained tumor control. #CancerTreatment #Oncology #ClinicalTrials #OncWeekly - @ElbazTehila - buff.ly/3WMsbWG
8
2 Aug 2024
Can ML improve PCR prediction in BC? Dive into the latest comparison of classifiers and find out! #Oncology #CancerResearch #BreastCancer #AIinMedicine #OncWeekly - buff.ly/4bWDWhL
15
31 Jul 2024
ICI Antiangio-Ab leads in safety for NSCLC post-ICI failure. #Oncology #CancerResearch #OncWeekly - buff.ly/4cN0iDi
19
30 Jul 2024
Study highlights potential of ARS model in LUAD treatment and prognosis. #Cancer #LungCancer #ClinicalTrials #OncWeekly buff.ly/3W8nGpm
12
29 Jul 2024
Improved survival in elderly glioblastoma patients through upfront resection. #CancerResearch #Glioblastoma #Oncology - buff.ly/3WywBAH
1
47
28 Jul 2024
Study: TKI Chemo superior for PFS, ORR; ICI TKI for OS in NSCLC post-ICI failure. #Cancer #OncWeekly - buff.ly/4cN0iDi
25
26 Jul 2024
Elevated CKS1B in LUAD cells promotes growth and invasion. #CancerResearch #Oncology #ClinicalTrials #OncWeekly buff.ly/3W8nGpm
16
24 Jul 2024
CLINICAL TRIAL - Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) buff.ly/3WurZv8
150